Sagimet Biosciences Email Format

Pharmaceutical ManufacturingCalifornia, United States11-50 Employees

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California. It focuses on developing therapies for liver disease, particularly nonalcoholic steatohepatitis (NASH), and for certain cancers, by targeting dysfunctional metabolic pathways. The company brings specialized expertise in fatty acid synthase biology and has built a platform of proprietary FASN inhibitors. Its pipeline includes denifanstat, a candidate in development aimed at modulating lipid metabolism.
Sagimet targets patients with NASH and selected cancers, addressing diseases where metabolic dysfunction and fibrotic pathways are relevant. As a small to mid-sized organization within the pharmaceutical sector, Sagimet continues its clinical-stage work and, in April 2026, announced the appointment of Andreas Grauer as Chief Medical Officer.

Sign up for free to view info

Company overview Employee directory